<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04046250</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-2690-0003</org_study_id>
    <nct_id>NCT04046250</nct_id>
  </id_info>
  <brief_title>Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690</brief_title>
  <acronym>TK112690</acronym>
  <official_title>Phase 2a, Multi-center, Placebo-controlled, Randomized, Partially Blinded, Study Infused TK112690 or or Placebo Administered Along With Methotrexate Weekly for Four Consecutive Weeks to Patients With Recurrent or Residual SCCHN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tosk, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crystal Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tosk, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will receive methotrexate at a dose of 45 mg/m2 administered weekly for 4&#xD;
      consecutive weeks as an iv infusion along with a nutritional supplement administered two&#xD;
      hours before the methotrexate. One hour before the methotrexate treatment the patients will&#xD;
      be administered the first infusion of the day of either TK112690 or placebo depending on&#xD;
      randomization. Five hours after the methotrexate treatment the patients will be administered&#xD;
      the second treatment of either TK112690 or placebo depending on randomization. The TK112690&#xD;
      dose will be 45 mg/kg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive methotrexate at a dose of 45 mg/m2 administered weekly for 4&#xD;
      consecutive weeks as an iv infusion along with a nutritional supplement administered two&#xD;
      hours before the methotrexate. One hour before the methotrexate treatment the patients will&#xD;
      be administered the first infusion of the day of either TK112690 or placebo depending on&#xD;
      randomization infusion. Five hours after the methotrexate treatment the patients will be&#xD;
      administered the second treatment of either TK112690 or placebo depending on randomization.&#xD;
      The TK112690 dose will be 45 mg/kg.&#xD;
&#xD;
        -  A total of 22 patients will be enrolled into one of 2 different dose groups: TK-112690&#xD;
           treated or placebo treated.&#xD;
&#xD;
        -  Screening must be within 15 days of subject enrollment.&#xD;
&#xD;
        -  Patients will remain for observation at the clinical site for a minimum of 25 hours post&#xD;
           initial TK112690 or placebo dose.&#xD;
&#xD;
        -  Study follow-up will occur on Week 6, two weeks after the last dosing of methotrexate.&#xD;
&#xD;
        -  Blinding: The study will be partially blinded. The patient and investigator will be&#xD;
           blinded as to whether TK112690 or placebo is administered. The CRO, sponsor, and site&#xD;
           pharmacist will know whether the patient was administered active drug or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A total of 22 patients will be enrolled into one of 2 different: TK112690 treated or placebo treated.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The study will be partially blinded. The patient and investigator will be blinded as to whether TK112690 or placebo is administered. The clinical research organization, sponsor, and site pharmacist will know whether the patient was administered active drug or placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mucositis</measure>
    <time_frame>up to 4 Weeks</time_frame>
    <description>Mucositis Evaluation Using Established Scoring Systems: NCI/CTCAE at 4 WKs (Primary) and WHO at 4 WKs (Primary).&#xD;
NCI/CTCAE=National Cancer Institute/Common Terminology Criteria for Adverse Events and WHO=World Health Organization&#xD;
NCI Grades- 0= No mucositis, 1=Mild mucositis (Painless ulcers, erythema, or mild soreness in the absence of lesions), 2=Moderate mucositis (Painful erythema, edema, or ulcers but eating or swallowing possible), 3= Severe mucositis (Painful erythema, edema, or ulcers requiring IV hydration), 4=Life threatening, 5=Death WHO Grades- 0=No mucositis, 1= Mild (Oral soreness, erythema), 2=Moderate (Oral erythema, ulcers, solid diet tolerated), 3=Severe (Oral ulcers, liquid diet only), 4=Life-threatening (Oral alimentation impossible).&#xD;
For both the scales above, a higher score implies greater mucositis.&#xD;
Scale specific mean values for patients in each group (placebo or treated) are calculated and compared by Student's t-test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence Adverse Events That Are Related to Treatment</measure>
    <time_frame>Measured Weekly Over 4 Weeks of Study</time_frame>
    <description>Tolerance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Mucositis</condition>
  <arm_group>
    <arm_group_label>TK112690</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TK112690 treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TK112690 formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TK-112690</intervention_name>
    <description>TK112690 treatment pre-methotrexate treatment</description>
    <arm_group_label>TK112690</arm_group_label>
    <other_name>Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo TK-112690</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male and female subjects over 18 years old with a histologically or cytological&#xD;
             confirmed diagnosis of locally residual, recurrent or metastatic SCCHN.&#xD;
&#xD;
          -  Subject must have failed at least one courses of non-MTX chemotherapy, or one course&#xD;
             of non-MTX chemotherapy and chemo radiation for treating their SCCHN.&#xD;
&#xD;
          -  No prior systemic treatments for cancer (chemotherapy and/or radiotherapy) 4 weeks&#xD;
             prior to screening.&#xD;
&#xD;
          -  No other concurrent, active, invasive malignancies.&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          -  Must have a life expectancy of at least 6 months.&#xD;
&#xD;
          -  History of brain metastases allowed if disease has stabilized or improved after&#xD;
             radiation and/or craniotomy.&#xD;
&#xD;
          -  No active angina or uncontrolled arrhythmia.&#xD;
&#xD;
          -  No detectable infection including hepatitis B/C and HIV.&#xD;
&#xD;
          -  Not pregnant or nursing. Women of childbearing potential must have a negative urine&#xD;
             pregnancy test at screening and on the day before dosing and must use medically&#xD;
             acceptable methods of birth control. Acceptable methods of birth control include oral&#xD;
             or transdermal contraceptives, condoms, spermicidal foam, IUD, progestin implant or&#xD;
             injection, abstinence, vaginal ring, or sterilization of partner. The reason for&#xD;
             non-childbearing potential, such as bilateral tubal ligation, bilateral oophorectomy,&#xD;
             hysterectomy, or post-menopausal for ≥ 1 year, must be specified in the patient's&#xD;
             medical history file and CRF.&#xD;
&#xD;
          -  Must have adequate organ and immune function as indicated by the following laboratory&#xD;
             values:&#xD;
&#xD;
        Parameter Laboratory Values Serum creatinine ≤1.5 x ULN Est. creatinine clearance ≥45&#xD;
        mL/min Total bilirubin ≤2.0 mg/dL (≤34.2 μmol/L) AST &amp; ALT ≤3 x ULN Absolute granulocytes&#xD;
        ≥1.5 x 109 cells/L Platelets ≥100,000/µL&#xD;
&#xD;
        ● Be able to read and understand, and provide a signature or thumb impression on the&#xD;
        Informed Consent Form (ICF) before entering the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has not failed at least one courses of non-MTX chemotherapy or one course of&#xD;
             non-MTX chemotherapy and chemo radiation for treating their SCCHN.&#xD;
&#xD;
          -  Uncontrolled active infection.&#xD;
&#xD;
          -  Current mucositis (&gt;Grade 1).&#xD;
&#xD;
          -  Pregnant or nursing mother.&#xD;
&#xD;
          -  Prior history of a cerebrovascular accident or hemorrhage.&#xD;
&#xD;
          -  Congestive heart failure, as defined by New York Heart Association class III or IV.&#xD;
&#xD;
          -  Uncontrolled hypertension.&#xD;
&#xD;
          -  Active psychiatric/mental illness making informed consent or useful clinical follow-up&#xD;
             unlikely.&#xD;
&#xD;
          -  Subjects who have previously been enrolled into this study and subsequently withdrew.&#xD;
&#xD;
          -  Subject receiving other investigational agent(s).&#xD;
&#xD;
          -  Any systemic immunosuppressive medication/therapy (eg, other chemotherapy, steroids).&#xD;
&#xD;
          -  Any significant systemic illness, unstable or severe medical condition(s) that could&#xD;
             put the subject at risk during the study, interfere with outcome measures, or affect&#xD;
             compliance with the protocol procedures such as intercurrent infection and/or&#xD;
             autoimmune disease, ie, any condition that compromises the immune system.&#xD;
&#xD;
          -  Known or suspected intolerance or hypersensitivity to the study materials (TK-112690&#xD;
             and/or excipients or closely related compounds).&#xD;
&#xD;
          -  Subjects, who have received, or plan to receive, radiation or chemotherapy within 4&#xD;
             weeks of screening.&#xD;
&#xD;
          -  Subjects that have a history of poor compliance in clinical research studies.&#xD;
&#xD;
          -  Subjects that have participated in any other investigative clinical trial in the past&#xD;
             4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Garland</last_name>
    <role>Study Director</role>
    <affiliation>Tosk, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bangalore Cancer</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560091</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karnatak Cancer Therapy and Research Institute</name>
      <address>
        <city>Navanagar</city>
        <state>Karnataka</state>
        <zip>580025</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netaji Subhash Chandra Bose Cancer Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700094</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <results_first_submitted>April 14, 2021</results_first_submitted>
  <results_first_submitted_qc>May 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 3, 2021</results_first_posted>
  <last_update_submitted>May 8, 2021</last_update_submitted>
  <last_update_submitted_qc>May 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucositis</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Uridine Phosphorylase Inhibitor</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT04046250/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TK112690</title>
          <description>TK112690 treatment&#xD;
TK-112690: TK112690 treatment pre-methotrexate treatment</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>TK112690 formulation&#xD;
Placebo TK-112690: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8">Four Methotrexate + TK-112690 Treatments</participants>
                <participants group_id="P2" count="7">Four Methotrexate + TK-12260 Placebo Treatments</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TK112690</title>
          <description>TK112690 treatment&#xD;
TK-112690: TK112690 treatment pre-methotrexate treatment</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>TK112690 formulation&#xD;
Placebo TK-112690: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="11"/>
                    <measurement group_id="B2" value="49" spread="13"/>
                    <measurement group_id="B3" value="52" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mucositis</title>
        <description>Mucositis Evaluation Using Established Scoring Systems: NCI/CTCAE at 4 WKs (Primary) and WHO at 4 WKs (Primary).&#xD;
NCI/CTCAE=National Cancer Institute/Common Terminology Criteria for Adverse Events and WHO=World Health Organization&#xD;
NCI Grades- 0= No mucositis, 1=Mild mucositis (Painless ulcers, erythema, or mild soreness in the absence of lesions), 2=Moderate mucositis (Painful erythema, edema, or ulcers but eating or swallowing possible), 3= Severe mucositis (Painful erythema, edema, or ulcers requiring IV hydration), 4=Life threatening, 5=Death WHO Grades- 0=No mucositis, 1= Mild (Oral soreness, erythema), 2=Moderate (Oral erythema, ulcers, solid diet tolerated), 3=Severe (Oral ulcers, liquid diet only), 4=Life-threatening (Oral alimentation impossible).&#xD;
For both the scales above, a higher score implies greater mucositis.&#xD;
Scale specific mean values for patients in each group (placebo or treated) are calculated and compared by Student's t-test.</description>
        <time_frame>up to 4 Weeks</time_frame>
        <population>Patients with SCCHN who have failed at least one prior treatment of chemotherapy and/or radiation</population>
        <group_list>
          <group group_id="O1">
            <title>TK112690</title>
            <description>TK112690 treatment&#xD;
TK-112690: TK112690 treatment pre-methotrexate treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>TK112690 formulation&#xD;
Placebo TK-112690: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mucositis</title>
          <description>Mucositis Evaluation Using Established Scoring Systems: NCI/CTCAE at 4 WKs (Primary) and WHO at 4 WKs (Primary).&#xD;
NCI/CTCAE=National Cancer Institute/Common Terminology Criteria for Adverse Events and WHO=World Health Organization&#xD;
NCI Grades- 0= No mucositis, 1=Mild mucositis (Painless ulcers, erythema, or mild soreness in the absence of lesions), 2=Moderate mucositis (Painful erythema, edema, or ulcers but eating or swallowing possible), 3= Severe mucositis (Painful erythema, edema, or ulcers requiring IV hydration), 4=Life threatening, 5=Death WHO Grades- 0=No mucositis, 1= Mild (Oral soreness, erythema), 2=Moderate (Oral erythema, ulcers, solid diet tolerated), 3=Severe (Oral ulcers, liquid diet only), 4=Life-threatening (Oral alimentation impossible).&#xD;
For both the scales above, a higher score implies greater mucositis.&#xD;
Scale specific mean values for patients in each group (placebo or treated) are calculated and compared by Student's t-test.</description>
          <population>Patients with SCCHN who have failed at least one prior treatment of chemotherapy and/or radiation</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NCI/CTCAE at 4 WKs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.19"/>
                    <measurement group_id="O2" value="2.84" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WHO at 4 WKs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.17"/>
                    <measurement group_id="O2" value="2.87" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Adverse Events That Are Related to Treatment</title>
        <description>Tolerance</description>
        <time_frame>Measured Weekly Over 4 Weeks of Study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TK112690</title>
            <description>TK112690 treatment&#xD;
TK-112690: TK112690 treatment pre-methotrexate treatment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>TK112690 formulation&#xD;
Placebo TK-112690: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Adverse Events That Are Related to Treatment</title>
          <description>Tolerance</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE GI and Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TK112690</title>
          <description>TK112690 treatment&#xD;
TK-112690: TK112690 treatment pre-methotrexate treatment</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>TK112690 formulation&#xD;
Placebo TK-112690: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Medra</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Medra</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Each of the three clinical sites has a PI. Each PI is bound by a CDA covering the clinical data.&#xD;
Tosk intends to prepare a manuscript reporting results from this trial combined with the results from the Phase 1b clinical trial. All the PIs will have a chance to review and approve the findings reported in the manuscript. Tosk expects to submit the manuscript for publication in early 2022.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Garland, PhD</name_or_title>
      <organization>Tosk, Inc.</organization>
      <phone>408.348.5164</phone>
      <email>wgarland@tosk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

